Christos K Fountzilas

机构：Roswell Park Comprehensive Cancer Center · ORCID：0000-0003-3837-5644

发表论文 284 篇 · 总被引 5778 次 · h-index 25

代表论文

• Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis (2026 · Nature Communications · 被引 12)
• HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors (2025 · Future Oncology · 被引 12)
• Pancreatic Steatosis as a Risk Factor for Pancreatic Ductal Adenocarcinoma: Pathogenesis and Clinical Implications (2025 · Clinical and Translational Gastroenterology · 被引 12)
• Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 11)
• Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2–targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma. (2025 · Journal of Clinical Oncology · 被引 6)
• Efficacy and safety of ASP3082 monotherapy or in combination with mFOLFIRINOX in patients (pts) with pancreatic ductal adenocarcinoma (PDAC). (2026 · Journal of Clinical Oncology · 被引 5)